Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Through 2027, the European market for large-joint reconstructive implants will expand slightly, with favorable demographic factors supporting procedure volumes. Economic constraints and market maturity will somewhat hinder growth and somewhat impede the use of novel technologies such as patient-specific 3-D–printed implants, robotic-assisted surgeries, and minimally invasive techniques.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for large-joint reconstructive implants in Europe across a 10-year period.
Europe-wide efforts to reduce health care costs and the rising presence of GPOs will result in price decreases for reconstructive implants.
Which countries and segments will be most affected, and why?
How will these cost and pricing pressures affect product uptake and ASPs?
Several product recalls and lawsuits have affected top manufacturers in the large-joint reconstructive implant space.
The new MDR will implement stringent protocols for assessing device efficacy and safety.
What impact will the MDR have on the European large-joint reconstructive implant market?
Will the new regulations affect the entrance of innovative technologies in Europe?
Technological advancements, such as robotic systems and 3-D printing, will expand the total pool of patients willing and able to undergo hip and knee replacements.
What are the advantages of robotic-assisted surgery, and how will it impact procedure volume growth?
How might trends in manufacturing relate to functional outcomes of large-joint replacements and surgeon adoption of implant brands?
Surgeons are influenced by national joint registry data when choosing hip and knee implants.
How has joint registry data affected adoption of the various types of hip and knee implants?
Which countries are more affected by clinical results associated with implants, and why?
Already a Client? Log in to access this report.
Swarnadip Dutta is a senior analyst on the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in cardiac rhythm management, interventional cardiology, vascular access, and vascular closure device markets. Swarnadip holds a Master's degree in Bioinformatics and Biotechnology from SRM University, an MBA in Operations Management, and a Six Sigma Green Belt certification from the Indian Statistical Institute. Follow Swarnadip on Twitter: @Swarnadip_DRG.